STOCK TITAN

Avidity Biosciences (RNAM) Net Income by Year

RNAM

Avidity Biosciences, Inc. reported a net loss of $684.6M in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 8 fiscal years, from 2018 to 2025, and the quarters Avidity Biosciences, Inc. has filed alongside them.

FY2025 annual
Net Income -$684.6M
YoY n/m
5Y CAGR n/m
Source SEC Filings Latest period FY2025, ended Dec 31, 2025 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

RNAM Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY25FilingFY24FilingFY23FilingFY22FilingFY21FilingFY20FilingFY19FilingFY18Filing
Net Income-$684.6Mn/m-$322.3Mn/m-$212.2Mn/m-$174.0Mn/m-$118.0Mn/m-$44.4Mn/m-$24.7Mn/m-$11.2M

RNAM Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ4'25FilingQ3'25FilingQ2'25FilingQ1'25FilingQ4'24FilingQ3'24FilingQ2'24FilingQ1'24FilingQ4'23FilingQ3'23FilingQ2'23FilingQ1'23Filing
Net Income-$237.1Mn/m-$174.4Mn/m-$157.3Mn/m-$115.8Mn/m-$102.3Mn/m-$80.4Mn/m-$70.8Mn/m-$68.9Mn/m-$60.4Mn/m-$52.4Mn/m-$47.0Mn/m-$52.4Mn/m

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Avidity Biosciences, Inc. financials

Frequently Asked Questions

Avidity Biosciences, Inc. reported a net loss of $684.6M in fiscal year 2025.

Avidity Biosciences, Inc. (RNAM) reported a $322.3M net loss in fiscal year 2024 and a $684.6M net loss in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.

Across the 8 fiscal years this page covers, Avidity Biosciences, Inc. (RNAM) net income went from -$11.2M in fiscal year 2018 to -$684.6M in fiscal year 2025.

Avidity Biosciences, Inc. (RNAM) reported -$237.1M in net income in Q4 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Avidity Biosciences, Inc. (RNAM) reported on that line in every period on record.